# CLL17 (NCT04608318)

> Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04608318
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: German CLL Study Group
- Conditions: Chronic Lymphoid Leukemia
- Interventions: Ibrutinib; Venetoclax; Obinutuzumab
- Enrollment: 897
- Primary outcome: Investigator-assessed progression-free survival (PFS)

## Commentary we found

- YouTube: 92
- Podcasts: 61
- X threads: 26

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=cll17-nct04608318

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04608318", "email": "<work email>"}; the inbox owner confirms by the emailed link.